Haemostasis disturbances in polycythemia vera and essential thrombocythemia

Abstract

chronic myeloproliferative neoplasms (MPN) are commonly associated with thrombohemorrhagic complications. Pathogenesis of this complications is connected with platelet, plasma and vascular disturbances of haemostasis as well as of blood rheological disorders. Thrombotic risk constantly outweighs the risk of haemorrhage. Pathogenesis of thrombotic complications during clinical course of polycythemia vera (PV) and essential thrombocythemia (ET) is complex and differentiated. Mechanism involved in thrombotic tendency have also been attributed to the JAK2 v617F mutation, a molecular hallmark of PV and ET. coagulation, fibrinolysis processes and inflammation are activated in myeloproliferative neoplasms. Therapeutic modalities diminish thrombotic risk.